Precision Wealth Strategies LLC Takes $1.02 Million Position in Theravance Biopharma, Inc. $TBPH

Precision Wealth Strategies LLC acquired a new stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) during the 1st quarter, Holdings Channel.com reports. The fund acquired 62,815 shares of the biopharmaceutical company’s stock, valued at approximately $1,019,000.

Several other large investors also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Theravance Biopharma by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock worth $32,289,000 after buying an additional 54,152 shares during the last quarter. State Street Corp boosted its holdings in shares of Theravance Biopharma by 4.4% during the 4th quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock valued at $20,616,000 after acquiring an additional 45,987 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Theravance Biopharma by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock worth $17,567,000 after acquiring an additional 40,734 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Theravance Biopharma by 12.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 858,957 shares of the biopharmaceutical company’s stock worth $16,072,000 after acquiring an additional 92,253 shares during the period. Finally, Arrowstreet Capital Limited Partnership purchased a new position in shares of Theravance Biopharma during the third quarter valued at approximately $10,611,000. 99.10% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 8th. Wall Street Zen lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. HC Wainwright lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating and boosted their target price for the company from $15.00 to $17.00 in a research note on Tuesday, July 7th. B. Riley Financial increased their price target on Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a report on Tuesday, April 7th. Finally, Weiss Ratings downgraded Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 27th. Eight investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $19.40.

Theravance Biopharma Stock Down 0.2%

NASDAQ TBPH opened at $16.93 on Friday. Theravance Biopharma, Inc. has a 52 week low of $10.82 and a 52 week high of $21.03. The firm has a market capitalization of $872.74 million, a P/E ratio of 7.70 and a beta of 0.17. The company has a 50-day moving average price of $16.62 and a 200-day moving average price of $17.17.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The business had revenue of $17.70 million during the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. As a group, equities research analysts anticipate that Theravance Biopharma, Inc. will post 1.54 EPS for the current year.

Insider Buying and Selling

In other news, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction on Monday, June 15th. The shares were sold at an average price of $16.39, for a total transaction of $218,216.46. Following the transaction, the senior vice president owned 232,457 shares in the company, valued at $3,809,970.23. This trade represents a 5.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 37,799 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $17.00, for a total transaction of $642,583.00. Following the sale, the insider directly owned 9,174,453 shares of the company’s stock, valued at approximately $155,965,701. The trade was a 0.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 350,011 shares of company stock valued at $6,008,309. 7.65% of the stock is owned by corporate insiders.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.